Cagla Buyukakcay has been provisionally suspended under Article 7.12.1 of the 2021 Tennis Anti-Doping Programme (the "Programme"), pending determination of the charge against her at a full hearing pursuant to Article 8 of the Programme.
Ms. Buyukakcay, a 32-year-old player from Turkey, provided a urine sample on 3 August 2021 in association with her participation in the WTA Winners Open, played in Cluj-Napoca, Romania from 2-8 August 2021. That sample was sent to the World Anti-Doping Agency (“WADA”) accredited laboratory in Montreal, Canada for analysis, and was found to contain Ractopamine. Ractopamine is a non-Specified Substance, which is prohibited under category S1 of the 2021 WADA Prohibited List (Anabolic Agents), and therefore also prohibited under the Programme. Positive tests for non-Specified Substances carry a mandatory Provisional Suspension.
Ms. Buyukakcay was sent a pre-charge notice of Anti-Doping Rule Violations under Articles 2.1 and 2.2 of the Programme (presence of a Prohibited Substance in a Player’s Sample, and use of that substance) on 5 October 2021 and exercised her right to apply to the Chair of the Independent Panel for an order that the otherwise applicable Provisional Suspension should not be imposed. The Chair of the Independent Panel issued his decision on 4 November 2021, in which he dismissed the application to not impose the Provisional Suspension.